VALENCIA BURLESON: Open Payments
NPI 1568973790 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,800 in 87 payments from 15 companies in 2025. Trend: 2023 $467 · 2024 $1,998 · 2025 $1,800
Food & beverage: $1,787Education: $13
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $361 |
| Janssen Biotech, Inc. | 17 | $332 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $249 |
| Ardelyx, Inc. | 10 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $158 |
| Madrigal Pharmaceuticals | 4 | $104 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
| Aimmune Therapeutics, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $58 |
Products named: TREMFYA, XIFAXAN, IBSRELA, ENTYVIO, RINVOQ, REZDIFFRA, SKYRIZI, LINZESS.
Industry payments across GA — which companies pay providers there.
